Efficacy of Rosuvastatin Combined with Danhong Injection in the Treatment of Unstable Angina Pectoris and Influence on Serum Levels of TNF-a, hs-CRP and IL-6 / 中国药师

ABSTRACT

Objective:To discuss the efficacy of rosuvastatin combined with Danhong injection in the treatment of unstable angina pectoris (UAP) and the influence on serum levels of TNF-α, hs-CRP and IL-6.Methods:Totally 72 patients with UAP were random-ly divided into the control group (n=36) and the observation group (n=36).All the patients received the conventional therapy .The control group was given rosuvastatin tablets ,10 mg,po, qd on the basis of the conventional therapy , while the research group was trea-ted with Danhong injection 30ml,ivd, qd on the basic of the control group .All the patients were treated for 2 weeks.The improvements of clinical symptoms and electrocardiogram , and the adverse reactions before and after the treatments were observed .The frequency of onset and duration before and after the treatment were recorded .The levels of blood lipid , TNF-α, hs-CRP and IL-6 before and after the treatment were detected .Results: The total effective rate of the observation group was 91.67％, which was significantly higher than that (72.22％) of the control group (P<0.05).The seizure frequency and duration of the research group were significantly low -er than those of the control group (P<0.05).After the treatment, the lipid indices such as TG, TC and LDL-C, and serum levels of TNF-α, hs-CRP and IL-6 of the two groups decreased significantly , while HDL-C significantly increased , and the differences were sta-tistically significant (P<0.05).The levels of TG, TC, LDL-C, TNF-a, hs-CRP and IL-6 were significantly lower in the observation group than those in the control group , while HDL-C was significantly higher than that in the control group (P<0.05).Conclusion:Danhong injection and rosuvastatin can effectively improve the clinical symptoms of UAP patients , reduce angina frequency and dura-tion, and decrease serum levels of TNF-a, hs-CRP and IL-6 to inhibit inflammation , which is safe and effective , and worthy of clinical application.